Abstract
Intravenous immunoglobulin (IVIg) is currently an accepted treatment for some autoimmune diseases and it has recently been used empirically in various other autoimmune conditions. This review discusses the role of IVIg in autoimmunity, mainly in systemic lupus erythematosus and systemic vasculitis. Clinical experience with IVIg, as well as its mechanisms of action with special emphasis on modulation of the idiotypic network, are also presented.
Original language | English |
---|---|
Pages (from-to) | 513-518 |
Number of pages | 6 |
Journal | Drugs of Today |
Volume | 35 |
Issue number | 7 |
DOIs | |
State | Published - 1 Jan 1999 |
Externally published | Yes |
ASJC Scopus subject areas
- General Medicine